Search results
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks via Yahoo Finance· 2 hours agoThis week, an FDA advisory committee unanimously recommended approval of Eli Lilly’s LLY Alzheimer's...
Is It Too Late to Buy Pfizer Stock?
The Motley Fool via AOL· 4 hours agoAre Pfizer's (NYSE: PFE) best days behind it? If the stock's critics are to be believed, the answer is an emphatic "yes, obviously," with issues like its...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 22 hours agoPfizer disclosed on May 7 that a child participating in another...
Studio Investment Management LLC Buys 2,236 Shares of Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 8 hours agoStudio Investment Management LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 2.1% during the 4th quarter, according to the company in its most ...
Pfizer Inc. (NYSE:PFE) Shares Sold by Public Employees Retirement System of Ohio
ETF DAILY NEWS· 9 hours agoPublic Employees Retirement System of Ohio reduced its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 1.8% during the 4th quarter, HoldingsChannel reports. The ...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 1 day agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 2 days agoDespite a bevy of promising updates for its cancer treatments, Pfizer stock remains trapped below a...
Pfizer: An Oversold Pharma Stock in Recovery
GuruFocus.com via Yahoo Finance· 2 days agoSome say the art of investing is the ability of catching falling knives. Pfizer Inc. (NYSE:PFE) shares have sold off in 2023 and represent an attractive...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 19 hours agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Sarepta Therapeutics gains as Pfizer failure removes overhang By Investing.com
Investing.com· 1 day agoSarepta Therapeutics (NASDAQ:SRPT) stock rose over 3% Thursday after Pfizer (NYSE:PFE) announced...